Share on StockTwits

ACADIA Pharmaceuticals (NASDAQ:ACAD) Director William Mcdowall Wells unloaded 15,000 shares of the company’s stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $23.03, for a total value of $345,450.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

A number of research firms have recently commented on ACAD. Analysts at Morgan Joseph initiated coverage on shares of ACADIA Pharmaceuticals in a research note on Thursday, May 15th. They set an “overweight” rating on the stock. Analysts at JPMorgan Chase & Co. initiated coverage on shares of ACADIA Pharmaceuticals in a research note on Thursday, May 15th. They set an “overweight” rating and a $33.00 price target on the stock. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $27.29.

Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) traded up 0.74% on Tuesday, hitting $23.10. The stock had a trading volume of 1,025,113 shares. ACADIA Pharmaceuticals has a one year low of $15.64 and a one year high of $32.00. The stock has a 50-day moving average of $19.97 and a 200-day moving average of $23.2. The company’s market cap is $2.286 billion.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings data on Tuesday, May 6th. The company reported ($0.19) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.13) by $0.06. On average, analysts predict that ACADIA Pharmaceuticals will post $-0.80 earnings per share for the current fiscal year.

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.